- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
- Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
- Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
- Matinas BioPharma Prices $10 Million Registered Direct Offering
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
- Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
More ▼
Key statistics
On Friday, Matinas BioPharma Holdings Inc (MTNB:ASQ) closed at 0.1756, 59.20% above the 52 week low of 0.1103 set on Aug 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1767 |
---|---|
High | 0.177 |
Low | 0.1673 |
Bid | 0.1756 |
Offer | 0.1758 |
Previous close | 0.1767 |
Average volume | 1.01m |
---|---|
Shares outstanding | 250.82m |
Free float | 244.48m |
P/E (TTM) | -- |
Market cap | 44.32m USD |
EPS (TTM) | -0.1056 USD |
Data delayed at least 15 minutes, as of May 10 2024 21:10 BST.
More ▼